Overview

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborator:

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.